IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

FACCHETTI, FLORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.314
NA - Nord America 4.369
AS - Asia 4.306
SA - Sud America 416
AF - Africa 99
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.543
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.178
GB - Regno Unito 1.910
CN - Cina 1.561
SG - Singapore 1.073
DE - Germania 832
IT - Italia 787
SE - Svezia 385
HK - Hong Kong 365
RU - Federazione Russa 333
BD - Bangladesh 322
FR - Francia 318
BR - Brasile 312
VN - Vietnam 213
IN - India 192
NL - Olanda 137
CA - Canada 121
TR - Turchia 119
JP - Giappone 118
UA - Ucraina 113
IE - Irlanda 101
KR - Corea 100
FI - Finlandia 94
DK - Danimarca 60
EU - Europa 54
ID - Indonesia 52
PL - Polonia 51
TW - Taiwan 47
MX - Messico 41
GR - Grecia 35
AR - Argentina 34
ES - Italia 34
AU - Australia 33
BE - Belgio 32
CO - Colombia 32
IQ - Iraq 25
AT - Austria 22
CI - Costa d'Avorio 19
CH - Svizzera 14
EG - Egitto 14
MA - Marocco 12
PH - Filippine 12
PK - Pakistan 12
CY - Cipro 11
EC - Ecuador 11
SA - Arabia Saudita 10
SL - Sierra Leone 10
UZ - Uzbekistan 10
DZ - Algeria 8
IR - Iran 8
KE - Kenya 8
PT - Portogallo 8
CZ - Repubblica Ceca 7
SK - Slovacchia (Repubblica Slovacca) 7
PE - Perù 6
VE - Venezuela 6
ZA - Sudafrica 6
BG - Bulgaria 5
CL - Cile 5
CR - Costa Rica 5
IL - Israele 5
JM - Giamaica 5
JO - Giordania 5
LT - Lituania 5
LU - Lussemburgo 5
MM - Myanmar 5
MY - Malesia 5
TH - Thailandia 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
GH - Ghana 4
NP - Nepal 4
PS - Palestinian Territory 4
PY - Paraguay 4
RO - Romania 4
UY - Uruguay 4
DO - Repubblica Dominicana 3
HN - Honduras 3
KG - Kirghizistan 3
NI - Nicaragua 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
ET - Etiopia 2
HR - Croazia 2
HU - Ungheria 2
KW - Kuwait 2
KZ - Kazakistan 2
MD - Moldavia 2
MN - Mongolia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
AL - Albania 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
Totale 14.575
Salva come PNG Salva come JPEG
Città #
Southend 1.744
Singapore 622
Ashburn 417
Chandler 354
Hong Kong 324
Beijing 300
San Jose 252
Milan 245
Frankfurt am Main 221
Dallas 171
Seattle 156
Wilmington 133
Ann Arbor 129
Princeton 126
Fairfield 122
Los Angeles 106
Council Bluffs 102
Dublin 99
New York 97
Santa Clara 85
Dearborn 84
Woodbridge 83
Jacksonville 81
Houston 77
Mountain View 77
Nanjing 76
Bengaluru 74
Shanghai 72
Hefei 68
Guangzhou 64
Lauterbourg 63
Hanoi 62
Ho Chi Minh City 61
Buffalo 58
Boardman 57
Tokyo 54
Toronto 52
Redmond 51
Des Moines 48
Moscow 48
Redwood City 48
Helsinki 47
Munich 36
Rome 36
Warsaw 35
Shenyang 34
Cambridge 33
São Paulo 33
Hangzhou 32
Phoenix 32
Serra 32
Hebei 31
Scranton 31
Andover 30
Columbus 30
Jakarta 30
Jinan 30
Kiez 30
Brussels 29
Sakarya 29
Changsha 28
Hanover 27
Bogotá 26
Somerville 26
Grafing 24
Zhengzhou 24
Roxbury 23
The Dalles 23
Tianjin 23
Istanbul 22
Nürnberg 22
Berlin 21
Seoul 21
Sunnyvale 21
Turin 21
Taichung 20
Abidjan 19
Chongqing 19
Nuremberg 18
Bari 17
Saint Petersburg 17
Shenzhen 17
Athens 16
Cangzhou 16
Chicago 16
Chengdu 15
Nanchang 15
Taipei 14
Da Nang 13
Kunming 13
Fuzhou 12
London 12
San Diego 12
Bologna 11
Brooklyn 11
Montreal 11
Naples 11
Ottawa 11
Rio de Janeiro 11
Auburn Hills 10
Totale 8.492
Salva come PNG Salva come JPEG
Nome #
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential 810
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs 600
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors 576
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 571
Unique expression and
localization of aquaporin- 4 and aquaporin-9 in murine and human neural stem
cells and in their glial progeny 474
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 429
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 396
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B 358
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 351
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 270
Cancer stem cells and therapeutic perspectives 266
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 261
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 255
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients 254
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy 247
BRAF V599E mutation occurs in Spitz and Reed nevi 238
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 234
Allelic inhibition of displacement activity : a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 226
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B 225
New perspectives in the treatment of melanoma : anti-angiogenic and anti-lymphoangiogenic strategies 224
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy 222
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 216
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 214
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance 213
CARATTERIZZAZIONE MOLECOLARE DELLA FARMACO-RESISTENZA IN PAZIENTI NAIVE CON EPATITE CRONICA B TRATTATI CON ENTECAVIR 210
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 208
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 204
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 203
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 203
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients 203
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 201
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection 200
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 200
Identification of stem cell like population in human melanoma 198
Knockdown of AQP1 in HMEC-1 cells and WM115 cells changes the organisation of the cytoskeleton 197
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 194
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 192
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 191
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 191
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients 185
Effect of a caloric restriction regimen on the angiogenic capacity of aorta and on the expression of endothelin-1 during ageing 184
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B 184
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 174
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 173
CD133 postive cellular population in human melanoma 170
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal 168
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 167
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide 164
Failure of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine 157
Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT 157
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta 154
CD133 positive cellular population in human melanoma 150
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B 147
TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues 144
Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV 141
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib : The ALICE-1 study 136
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection 132
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B 114
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide 114
Reticulohistiocytosis 106
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension 103
Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods 102
Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients 95
Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B 90
Erheim-Chester disease 90
Introduction to histiocytic and dendritic cell neoplasms 84
Indeterminate cell histiocytosis/indeterminate dendritic cell tumour 76
Langerhans cell histiocytosis 73
Defect of regulatory T cells in patients with Omenn syndrome 64
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study 14
Dynamics of HBV biomarkers during nucleos(t)ide analog treatment: A 14-year studY 12
Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases 8
HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D 6
Totale 15.163
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.449
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.449
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021146 0 0 0 0 0 0 0 0 0 0 0 146
2021/20221.004 74 47 51 62 67 60 79 74 89 126 64 211
2022/20231.157 135 148 106 114 114 197 35 86 128 18 49 27
2023/2024852 37 62 44 37 184 45 83 65 49 50 79 117
2024/20251.864 85 171 55 173 125 84 97 164 95 192 190 433
2025/20264.301 450 309 452 305 335 283 504 191 372 298 658 144
Totale 15.163